GSK's consumer health spinout Haleon started trading on the London Stock Exchange this morning, making its debut with a price of 330 pence and a market valuation of around £31 billion ($37 billion).

Haleon was formed in 2022 from a combination of GSK and Pfizer’s consumer-health units. Pfizer has been cutting down its stake in Haleon, most recently raising £2.5 billion through a block ...

Haleon was a consumer health joint venture (JV), an over-the-counter (OTC) medicines business jointly created by Pfizer and GSK plc. GSK in 2019. GSK owned a controlling stake of 68% in the ...

Pfizer will sell about 662 million ordinary shares, or 7.3%, of Haleon, created in a merger of GSK and Pfizer's consumer healthcare businesses in 2019, and spun off in 2022. Under the deal ...